| Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression P Kuehl, J Zhang, Y Lin, J Lamba, M Assem, J Schuetz, PB Watkins, ... Nature genetics 27 (4), 383-391, 2001 | 2336 | 2001 |
| Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications GP Aithal, CP Day, PJL Kesteven, AK Daly The Lancet 353 (9154), 717-719, 1999 | 1572 | 1999 |
| Estimation of the warfarin dose with clinical and pharmacogenetic data International Warfarin Pharmacogenetics Consortium New England Journal of Medicine 360 (8), 753-764, 2009 | 1536 | 2009 |
| The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen EA Sconce, TI Khan, HA Wynne, P Avery, L Monkhouse, BP King, P Wood, ... Blood 106 (7), 2329-2333, 2005 | 1155 | 2005 |
| Metabolic gene polymorphism frequencies in control populations S Garte, L Gaspari, AK Alexandrie, C Ambrosone, H Autrup, JL Autrup, ... Cancer Epidemiology and Prevention Biomarkers 10 (12), 1239-1248, 2001 | 1044 | 2001 |
| HLA-B* 5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin AK Daly, PT Donaldson, P Bhatnagar, Y Shen, I Pe'er, A Floratos, MJ Daly, ... Nature genetics 41 (7), 816-819, 2009 | 950 | 2009 |
| A randomized trial of genotype-guided dosing of warfarin M Pirmohamed, G Burnside, N Eriksson, AL Jorgensen, CH Toh, ... N Engl J Med 369, 2294-2303, 2013 | 772 | 2013 |
| Case definition and phenotype standardization in drug‐induced liver injury GP Aithal, PB Watkins, RJ Andrade, D Larrey, M Molokhia, H Takikawa, ... Clinical Pharmacology & Therapeutics 89 (6), 806-815, 2011 | 697 | 2011 |
| Nomenclature for human CYP2D6 alleles. AK Daly, J Brockmöller, F Broly, M Eichelbaum, WE Evans, FJ Gonzalez, ... Pharmacogenetics 6 (3), 193-201, 1996 | 550 | 1996 |
| Homozygosity for the patatin‐like phospholipase‐3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease L Valenti, A Al‐Serri, AK Daly, E Galmozzi, R Rametta, P Dongiovanni, ... Hepatology 51 (4), 1209-1217, 2010 | 523 | 2010 |
| TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease YL Liu, HL Reeves, AD Burt, D Tiniakos, S McPherson, JBS Leathart, ... Nature communications 5 (1), 1-6, 2014 | 417 | 2014 |
| Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics M Niemi, JT Backman, LI Kajosaari, JB Leathart, M Neuvonen, AK Daly, ... Clinical Pharmacology & Therapeutics 77 (6), 468-478, 2005 | 392 | 2005 |
| Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles MI Lucena, M Molokhia, Y Shen, TJ Urban, GP Aithal, RJ Andrade, ... Gastroenterology 141 (1), 338-347, 2011 | 366 | 2011 |
| Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis J Grove, AK Daly, MF Bassendine, CP Day Hepatology 26 (1), 143-146, 1997 | 364 | 1997 |
| The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants J Zhang, P Kuehl, ED Green, JW Touchman, PB Watkins, A Daly, SD Hall, ... Pharmacogenetics and Genomics 11 (7), 555-572, 2001 | 354 | 2001 |
| Common allelic variants of cytochrome P4503A4 and their prevalence in different populations JK Lamba, YS Lin, K Thummel, A Daly, PB Watkins, S Strom, J Zhang, ... Pharmacogenetics and Genomics 12 (2), 121-132, 2002 | 349 | 2002 |
| The role of individual human cytochrpmes P450 in drug metabolism and clinical response S Cholerton, AK Daly, JR Idle Trends in pharmacological sciences 13, 434-439, 1992 | 347 | 1992 |
| Meta-and pooled analyses of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk S Benhamou, WJ Lee, AK Alexandrie, P Boffetta, C Bouchardy, ... Carcinogenesis 23 (8), 1343-1350, 2002 | 335 | 2002 |
| Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients12 E Thervet, D Anglicheau, B King, MH Schlageter, B Cassinat, P Beaune, ... Transplantation 76 (8), 1233-1235, 2003 | 321 | 2003 |
| Mutant debrisoquine hydroxylation genes in Parkinson's disease M Armstrong, AK Daly, S Cholerton, JR Idle, DN Bateman The Lancet 339 (8800), 1017-1018, 1992 | 314 | 1992 |
